Xu Xiao-Xu, Zhang Lei, Jiang Bo, Sun Jin, Liu Xiao-Hua, Zhang Sheng, Li Yan
Beijing University of Chinese Medicine, Beijing 100029, China.
The First Department of Sports Medicine, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.
Zhongguo Gu Shang. 2024 Apr 25;37(4):387-91. doi: 10.12200/j.issn.1003-0034.20231263.
To study the incidence rate of sinus tarsi syndrome after lateral ankle sprain and observe the clinical efficacy of sinus tarsal corticosteroid injections.
From January 2021 to Janury 2022, 391 patients with lateral ankle sprain and 88 patients with sinus tarsi syndrome using corticosteroid injections (compound betamethasone 1 ml+ lidocaine hydrochloride 4 ml) were retrospectively analyzed. There were 22 males and 66 females, aged from 29 to 60 years old with an average of (41.00±7.52) years old, duration of the disease from 1 to 12 months with an average of (5.6±4.2) months. The visual analogue scale(VAS) and American Orthopedic Foot and Ankle Society(AOFAS) scores were collected before, 1 month, 3 months, 6 months, and 12 months after treatment.
All 88 patients completed a 12-month follow-up. The incidence rate of sinus tarsi syndrome after lateral ankle sprain was 22.5%. One month after treatment, VAS was 1.20±0.89, AOFAS score was 88.70±7.04. Three months after treatment, VAS was 1.60±1.35, AOFAS score was 85.20±10.95. Six months after treatment, VAS 2.35±1.39, AOFAS 80.30±9.75. Twelve months after treatment, VAS was 2.80±1.51, AOFAS score was 79.1±9.94. Significant differences were found before and after treatment at all four time points of follow-up(<0.05).
The results of this study showed that the incidence rate of sinus tarsi syndrome after lateral ankle sprain was 22.5%. Corticosteroid injections were effective in the short term with a 65% recurrence rate of symptoms within 1 year. For patients with no significant long-term effect of conservative treatment, clinicians may explore alternative approaches, including options like ankle arthroscopy.
研究外侧踝关节扭伤后距下窦综合征的发病率,并观察距下窦皮质类固醇注射的临床疗效。
回顾性分析2021年1月至2022年1月期间391例外侧踝关节扭伤患者及88例接受皮质类固醇注射(复方倍他米松1 ml + 盐酸利多卡因4 ml)治疗的距下窦综合征患者。其中男性22例,女性66例,年龄29至60岁,平均(41.00±7.52)岁,病程1至12个月,平均(5.6±4.2)个月。收集治疗前、治疗后1个月、3个月、6个月及12个月的视觉模拟评分(VAS)和美国矫形足踝协会(AOFAS)评分。
88例患者均完成12个月随访。外侧踝关节扭伤后距下窦综合征的发病率为22.5%。治疗1个月后,VAS为1.20±0.89,AOFAS评分为88.70±7.04。治疗3个月后,VAS为1.60±1.35,AOFAS评分为85.20±10.95。治疗6个月后,VAS为2.35±1.39,AOFAS为80.30±9.75。治疗12个月后,VAS为2.80±1.51,AOFAS评分为79.1±9.94。随访的四个时间点治疗前后差异均有统计学意义(<0.05)。
本研究结果显示外侧踝关节扭伤后距下窦综合征的发病率为22.5%。皮质类固醇注射短期内有效,但1年内症状复发率为65%。对于保守治疗无明显长期效果的患者,临床医生可探索其他治疗方法,如踝关节镜检查等。